Jason Kolbert analyst

Currently out of the existing stock ratings of Jason Kolbert, 424 are a BUY (95.71%), 2 are a SELL (0.45%), 17 are a HOLD (3.84%).

Jason Kolbert

Work Performance Price Targets & Ratings Chart

Analyst Jason Kolbert, carries an average stock price target met ratio of 37.92% that have a potential upside of 34.68% achieved within 421 days. Previously, Jason Kolbert worked at DAWSON JAMES.

Jason Kolbert’s has documented 762 price targets and ratings displayed on 69 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on URGN, UroGen Pharma Ltd at 03-Oct-2025.

Wall Street Analyst Jason Kolbert

Analyst best performing recommendations are on IVVD (INVIVYD).
The best stock recommendation documented was for IVVD (INVIVYD) at 8/25/2025. The price target of $1 was fulfilled within 1 day with a profit of $0.44 (78.57%) receiving and performance score of 785.71.

Average potential price target upside

ADMP Adamis Pharma AEZS Aeterna Zentaris ATHX Athersys BCLI Brainstorm Cell Therapeutics BLRX BioLineRx Ltd CTXR Citius Pharmaceuticals FBIO Fortress Biotech GILD Gilead Sciences GLMD Galmed Pharmaceuticals Ltd INO Inovio Pharmaceuticals ISR IsoRay MESO Mesoblast Ltd MNKD MannKind Corp NTEC Intec Pharma Ltd OMER Omeros PSTI Pluristem SRNE Sorrento Therape ACHN Achillion Pharmaceuticals CLBS Caladrius Biosciences TEVA Teva Pharma Industries Ltd ADR VRTX Vertex Pharmaceuticals AVXL Anavex Life Sciences Corp PSTV Plus Therapeutics PRPH ProPhase Labs BCDA Biocardia  ADMA ADMA Biologics BGNE BeiGene Ltd CFRX ContraFect Corp CHEK Check Cap Ltd SNGX Soligenix CANF Can Fite Biopharma Ltd ADR ONCS OncoSec Medical DYAI Dyadic International ABUS Arbutus Biopharma Corp CHRS Coherus BioSciences CTSO Cytosorbents Crp DARE Dare Bioscience ANVS Annovis Bio  ARTL Artelo Biosciences BMEA Biomea Fusion IBRX Immunitybio CLNN Clene CMPX Compass Therapeutics CRMD CorMedix ENLV Enlivex Therapeutics Ltd GOVX GeoVax Labs HOTH Hoth Therapeutics HUMA Humacyte IMUX Immunic IVVD Invivyd NRXP NRX Pharmaceuticals RCEL Avita Medical Ltd RVPH Reviva Pharmaceuticals Holdings TRVI Trevi Therapeutics URGN UroGen Pharma Ltd BJDX Bluejay Diagnostics CLGN Collplant Biotechnologies Ltd COYA Coya Therapeutics, Common Stock CRVO CervoMed MNOV MediciNova SNOA Sonoma Pharmaceuticals FBLG FibroBiologics, Common Stock BNTC Benitec Biopharma Ltd ADR CKPT Checkpoint Therapeutics CNTX Context Therapeutics IMAC Imac Holdings INDP Indaptus Therapeutics MBOT Microbot Medical NBY NovaBay Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

5 years 4 months 22 days ago
(13-May-2020)

0/2 (0%)

$7.2 (167.00%)

Hold

5 years 10 months 9 days ago
(26-Nov-2019)

0/1 (0%)

$1.7 (32.08%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Kolbert is most bullish on?

Potential upside of $36.04 has been obtained for AVXL (ANAVEX LIFE SCIENCES CORP)

Which stock is Jason Kolbert is most reserved on?

Potential downside of -$0.16 has been obtained for IVVD (INVIVYD)

What Year was the first public recommendation made by Jason Kolbert?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?